Five-Year Results of Transcatheter Mitral Valve Repair

Transcatheter edge-to-edge repair sustained its overall advantage over guideline-directed medical therapy alone in the COAPT randomized trial.

In the manufacturer-funded, randomized COAPT trial (NCT01626079), involving patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation (MR), transcatheter edge-to-edge repair (TEER) with MitraClip sustained its outcome advantages over guideline-directed medical therapy (GDMT) at 3 years (NEJM JW Cardiol Mar 8 2021 and J Am Coll Cardiol 2021; 77:1029). The investigators now report 5-year outcomes for the 534 patients with available data (89% of TEER group, 85% of GDMT-only group).

The annualized rate of hospitalization for heart failure through 5 years was significantly lower in the TEER group than the control group (33% vs. 57%; hazard ratio, 0.53), as it was for death (57% vs. 67%; HR, 0.72). Rates showed si…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)